No Picture
Trading Ideas

Betterment Review: A Perfect App For Hands-Off Investors

Robo-advisors are all the rage for some investors. In this Betterment review, we’ll take a close look at how it stacks up against the competition. And while we’re at it, we’ll also compare it to traditional human advisors.

Opening up a Betterment account online is simple. You just need a functioning email address and some basic pieces of information. Once you get in, you do need to provide Betterment with your address, date of birth, tax filing status employment level and income level.
It’s worth noting that to open an account, you also need to provide your social security number. This may …read more […]

No Picture
Trading Ideas

Polen Capital is Betting on Alibaba Group Holding (BABA) Stock

Polen Capital Management recently released its Q3 2020 Investor Letter, a copy of which you can download here. During the third quarter of 2020, the Polen Global Growth Composite Portfolio returned 9.09% gross of fees, while the MSCI All Country World Index was up 8.14%. You should check out Polen Capital’s top 5 stock picks […] …read more […]

No Picture
Trading Ideas

Is PayPal Holdings (PYPL) a Smart Long-term Buy?

Polen Capital Management recently released its Q3 2020 Investor Letter, a copy of which you can download here. During the third quarter of 2020, the Polen Global Growth Composite Portfolio returned 9.09% gross of fees, while the MSCI All Country World Index was up 8.14%. You should check out Polen Capital’s top 5 stock picks […] …read more […]

No Picture
Trading Ideas

Remdesivir’s Approval for Covid Doesn't Erase Doubts

(Bloomberg Opinion) — Gilead Sciences Inc.’s remdesivir, now under the brand name Veklury, reached another milestone Thursday. It is now the first medicine to get full Food and Drug Administration approval to treat Covid-19. Investors seem to see the nod as a boost to the drug’s prospects, sending shares up more than 4% in early trading Friday after a recent slump. The agency’s decision isn’t likely to dramatically expand the use of the medicine, which has been available to patients through emergency use authorization since May. The data surrounding its modest benefit has become muddier, and it’s not clear why …read more […]